Active Filter(s):
Details:
ACI’s rBV-Sf9-AAV platform is based on single use technology, utilizes suspension cell culture free of fetal bovine serum and uses non-animal derived material throughout the manufacturing process.
Lead Product(s): rAAV-based Gene Therapy
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022